VitaNova Life Sciences (VNOV) Accumulated Expenses (2017 - 2026)

VitaNova Life Sciences (VNOV) reported Accumulated Expenses of $81951.0 for Q1 2026, up 19.27% quarter-over-quarter from $68713.0 in Q4 2025.

VitaNova Life Sciences (VNOV) Accumulated Expenses (2017 - 2026) Analysis & Trends

VitaNova Life Sciences has reported Accumulated Expenses for 5 years, with the latest figure at $81951.0 in Q1 2026.

For the quarter ending Q1 2026, Accumulated Expenses changed N/A year-over-year to $81951.0; the trailing twelve-month figure through Jan 2026 stood at $81951.0 (changed N/A YoY), and the FY2025 full-year result was $60885.0, changed N/A from the prior year.
Accumulated Expenses for Q1 2026 stood at $81951.0, up from $68713.0 in the prior quarter.
The five-year high for Accumulated Expenses was $81951.0 in Q1 2026, with the low at $60885.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Akso Health	2,315,158.81 Bn	2,315,158.63 Bn	-
2	Mckesson	92.76 Bn	89.18 Bn	4.04 Bn
3	Cencora	52.82 Bn	50.83 Bn	3.59 Bn
4	Cardinal Health	52.17 Bn	48.39 Bn	2.50 Bn
5	Henry Schein	9.19 Bn	9.71 Bn	1.07 Bn
6	Accendra Health	246.88 Mn	-90.00 Mn	312.39 Mn
7	Edap Tms	161.92 Mn	146.92 Mn	8.15 Mn
8	111	107.47 Mn	25.61 Mn	23.58 Mn
9	Cosmos Health	9.42 Mn	7.26 Mn	1.38 Mn
10	VitaNova Life Sciences	-	-	316,343.00

Download Data